Tandem Diabetes Care, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John F. Sheridan
- Full Time Employees
- 2,650
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 11075 Roselle Street San Diego CA United States of America 92121
- IPO Date
- Nov 14, 2013
- CIK
- 0001438133
- Website
- tandemdiabetes.com
- Similar Companies
- Business
- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) designs, develops, manufactures and commercializes advanced automated insulin delivery systems and related products for people with insulin-dependent diabetes, including type 1 and type 2 diabetes; its core offerings include the t:slim X2 insulin pump with integrated color touchscreen and Control-IQ+ advanced hybrid closed-loop technology featuring predictive algorithms with AutoBolus capability for ages 2+ (type 1) and 18+ (type 2), the Tandem Mobi system as a compact tubeless insulin pump with smartphone control (iOS), 200-unit insulin capacity, Dexcom G6/G7 continuous glucose monitoring compatibility and inductive wireless charging, infusion sets with varied cannula materials, tubing lengths and insertion angles, t:connect diabetes management software for data visualization and remote software updates, and innovative mobile/cloud-based applications for therapy monitoring; the company also provides 24/7 support, expert training and limited warranties. Founded in 2006 and headquartered in San Diego, California, Tandem operates globally with sales in the United States and international markets, targeting people with diabetes, healthcare providers and distribution channels including durable medical equipment and pharmacy rebates covering approximately 20% of U.S. lives; it maintains partnerships with Dexcom for CGM integration, Abbott, Unomedical (Convatec) for infusion sets and the University of Virginia Center for Diabetes Technology for fully automated closed-loop research. Recent developments include U.S. FDA clearance for Control-IQ+ expansion to type 2 diabetes patients, successful 2024 U.S. launch of Tandem Mobi via multi-channel strategy with quarter-over-quarter shipment growth, completion of the 2024 Tandem Choice program, return to positive free cash flow, maintenance of full-year revenue guidance at $1 billion with double-digit growth focus, international shift to direct sales for higher average selling prices, sales force expansion, planned 2026 commercial launch of tubeless Mobi to capture type 2 market share, and 2023 acquisition of AMF Medical SA to integrate the Sigi rechargeable patch pump technology into its portfolio.
Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
3 Stocks to Invest in as Broker Rating Upgrades Signal Upside
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
TNDM Stock: What to Know About Tandem's 2026 Reset
Tandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Score of 62 Tells Investors
Silver Economy Investing: Why the Healthcare Giants Are in Focus
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care Q1 Earnings Call Highlights
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Compared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key Metrics
Tandem Diabetes Care Announces First Quarter 2026 Financial Results
Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
Tandem Diabetes Care Inc (TNDM) Shares Surge 4.8% -- What GF Score of 74 Tells Investors